Commercial breakthrough for Prostatype Genomics in Switzerland
Prostatype Genomics has received the first order of Prostatype® in Switzerland from one of the country's major university hospitals. It is a breakthrough for the company, where the focus now is on ensuring routine use through continued close collaboration with the customer and expanding the use of Prostatype® to additional leading hospitals in the country. The revenue will be booked in Q4 2023.Prostatype Genomics has received the first order for the company's product Prostatype® in Switzerland, one of the company's priority target markets. Prostatype® is a genetic test for assessing the